Senti Biosciences Inc. (SNTI)
3.88
0.07 (1.84%)
At close: Jan 15, 2025, 12:05 PM
undefined% (undefined)
| Bid | 3.85 |
| Market Cap | 17.80M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -15.59 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 3.89 |
| Volume | 13,229 |
| Avg. Volume (20D) | 2,371,408 |
| Open | 3.97 |
| Previous Close | 3.81 |
| Day's Range | 3.82 - 3.97 |
| 52-Week Range | 1.52 - 16.94 |
| Beta | undefined |
About SNTI
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor onc...
Industry Biotechnology
Sector Healthcare
IPO Date May 26, 2021
Employees 48
Stock Exchange NASDAQ
Ticker Symbol SNTI
Website https://www.sentibio.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SNTI stock is "Strong Buy." The 12-month stock price forecast is $12, which is an increase of 209.38% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Senti Biosciences Inc. is scheduled to release its earnings on Mar 20, 2025,
during market hours.
Analysts project revenue of $2.80M, reflecting a n/a YoY growth and earnings per share of -3.13, making a -25.48% decrease YoY.
Analysts project revenue of $2.80M, reflecting a n/a YoY growth and earnings per share of -3.13, making a -25.48% decrease YoY.
1 month ago ·
Source
+362.96%
Senti Biosciences shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago ·
Source
+10.15%
Senti Biosciences shares are trading higher after the company announced a year-over-year increase in Q2 EPS results.
